UK biotech fundraising picks up with best quarterly total since 2021

London, United Kingdom, 9 November 2023 - The UK biotech sector secured a substantial total of £563 million in venture capital and public financing during the three months spanning June to August 2023, data published today by the UK BioIndustry Association (BIA) and Clarivate shows.

This represents a 48% increase from the previous quarter's takings and consistent quarter-on-quarter growth throughout the year making this the most robust period since the sector’s peak in 2021. This is in line with the surge in fundraising activity among European companies that more than doubled their fundraisings this quarter, while US companies saw a 21% decline across all fundraisings.

While the dearth of public market launches continues to present challenges for European companies, including UK biotech companies, public follow-on financings were responsible for the increased investment this quarter, with UK companies raising a total of £315 million after a year of subdued activity.

Venture capital funding amounted to £249 million, representing a 26% decline compared to the previous quarter but still a 35% increase from the same period last year. Although fewer deals took place, early-stage companies were well-supported, with many deals falling into seed and series A categories.

Steve Bates OBE, CEO of the BIA, said:

"Against a difficult economic backdrop, the quality of the science and management teams in UK biotech is continuing to attract domestic and foreign investors. Strong seed and Series A dealmaking bodes well for company formation through 2023 and UK biotechs remain the European leaders for total venture capital raised. With the Jefferies London Healthcare conference becoming the pre-eminent global life sciences financing conference, all eyes are on the UK, and it is great to see us demonstrating success.

New initiatives stemming from the Mansion House Agreement help to give confidence for the UK financing ecosystem, with pension savers well placed to benefit if the pensions industry engages with this UK success story.”

“Globally, 2023 remains challenging for biotech, with the IPO window still closed. However, this quarter's total of £563 million is the highest we've seen since the record-breaking year of 2021 and is an encouraging sign that the global funding malaise is starting to recede. "

Mike Ward, Global Head of Life Sciences & Healthcare Thought Leadership, Clarivate, said:

"With world events such as wars in Ukraine and the Middle East and geopolitical tensions and the macroeconomic headwinds of persistent high-interest rates, it is hardly surprising that there has been a flight from riskier asset classes.

“Even though big pharma is sitting on big cash piles, and venture capitalists have billions in dry powder, there has been a reluctance to deploy the capital. Consequently, across the globe, biotech companies have struggled to raise new money.

“On a more positive note, we are seeing more enthusiasm for licensing and M&A deals as big pharma looks to replenish its pipelines.”  

The encouraging report follows recent efforts to unlock capital from pension funds to further boost investment into high-growth and innovative companies propelling the UK's life sciences sector to surpass last year's total fundraisings.

In his Autumn Statement, Chancellor Jeremy Hunt is expected to unveil a government initiative aimed at turbocharging pension funds' investments in high-growth private companies, one of the key goals of the Mansion House compact launched earlier this year.


Notes to Editors


About the BioIndustry Association (BIA)

The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow, and deliver world-changing innovation.

Helping biotech and life sciences sector to influence, connect and save. 


More news and updates 

BIA joins European Biosolutions Coalition

BIA has today joined the European Biosolutions Coalition, adding UK representation to this influential group. The European Biosolutions Coalition is an initiative established by several industry organisations to elevate the prominence of biosolutions on the European agenda.

New boost for TechBio companies seeking investment

The Francis Crick Institute’s start-up accelerator KQ Labs and the UK Bioindustry Association (BIA) have launched a new programme to support growing companies working at the interface of biology and data technologies.

State of the Discovery Nation report reveals the extent of sector's perfect storm

New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.

BIA teams up with top UK engineering biology stakeholders to champion the UK at SynBioBeta 2024

BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.

Post-Brexit border paperwork and inspections postponed for life sciences sector

Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.

BIA responds to Spring Budget 2024: highlights for UK life sciences

Three highlights for UK life sciences: first, the new expert advisory panel for the HMRC is a smart way to maximise the efficiency of R&D tax relief support for life science innovators; secondly, Alan Marchington’s ICG winning the LIFTs scheme shows real movement to unlock pension funds for life sciences; thirdly, AstraZeneca’s investment in next-generation manufacturing in Speke and Cambridge shows the strength of our ecosystem.

Deep Biotech will deliver a more sustainable future, and BIA is its new voice

Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future. 

Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner

Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.

Resilient UK biotech sector lands £1.8 billion investment in 2023

New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.   

BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides  

The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.  


More within